First published: 25 September 2026
Concept: what it measures
When someone leaves a job that included employer-paid private medical insurance (PMI), most UK group schemes offer a continuation option: the leaver can take over the same policy individually, at their own cost, without a fresh round of medical underwriting. The alternative is letting the group policy lapse and applying for a brand-new individual PMI policy later, which usually carries a cheaper headline premium but starts underwriting from scratch — meaning any condition that arose, was treated, or was even investigated during the employment period can be excluded, sometimes permanently. This test weighs the extra cost of continuation against the value of the underwriting protection it preserves, so the decision isn't made on premium price alone.
The formula
Continuation Extra Cost = (Continuation premium − comparable new individual-policy premium) × number of years the policy is expected to be held
Exclusion Risk Value = estimated cost of future private treatment for any condition that arose, was diagnosed, or was treated during the group scheme period, that a fresh underwriting review would be likely to exclude
Decision rule: if the Exclusion Risk Value is larger than the Continuation Extra Cost, exercising the continuation option is the stronger financial move, because it locks in cover for a condition a new insurer would likely carve out. If there's no meaningful health history from the employment period, or the condition in question is minor and unlikely to need future private treatment, letting the policy lapse and shopping for a new, cheaper individual policy is usually the better value.
UK Worked Example
Consider Daniel, a 46-year-old in Manchester who is leaving a job after four years of employer-paid group PMI. During that period, he was treated privately for a torn meniscus, with a realistic prospect of needing further knee treatment within the next five years.
- Continuation premium (individual rate, same insurer, underwriting terms preserved): £96/month
- Comparable new individual policy from a different insurer, fresh medical underwriting: £61/month
- Monthly premium gap: £96 − £61 = £35
- Intended holding period: 5 years
- Continuation Extra Cost: £35 × 60 months = £2,100
- Estimated cost of a further private knee procedure and related physiotherapy if it were excluded under a fresh policy: £6,500, based on typical UK private orthopaedic treatment pricing
Because the Exclusion Risk Value (£6,500) comfortably exceeds the Continuation Extra Cost (£2,100), Daniel is better off exercising the continuation option, even though the monthly premium is noticeably higher, because the new-policy route would very likely apply a moratorium or full-underwriting exclusion on his knee — the exact condition he's most likely to need treatment for again.
A second UK worked example: when lapsing is the better move
Consider Sofia, a 33-year-old in Leeds leaving a group scheme after eighteen months with no claims and no ongoing health issues.
- Continuation premium: £58/month; comparable new individual policy: £34/month
- Monthly gap: £24; intended holding period: 5 years
- Continuation Extra Cost: £24 × 60 = £1,440
- Exclusion Risk Value: negligible, since there's no treated condition from the employment period a new insurer would have grounds to exclude
Here the Continuation Extra Cost has nothing to weigh against, so letting the group policy lapse and applying fresh for the cheaper individual policy is the clearer financial choice.
Why there's no US parallel
Employer-paid group PMI with an individual continuation option is a specifically UK-shaped product, sitting alongside the NHS as supplemental cover rather than as primary coverage. The closest US analog — continuing employer coverage after leaving a job — is COBRA, already addressed by the Shield and Strategy COBRA vs. Marketplace Break-Even Calculator, but the mechanics differ in one important way: COBRA continues the same employer group plan at the same underwriting terms by law for a defined period, whereas the ACA Marketplace alternative involves no new medical underwriting at all, since ACA plans cannot exclude pre-existing conditions. The PMI continuation decision exists precisely because UK individual PMI, unlike ACA Marketplace plans, can still underwrite and exclude on a fresh application — a genuine cross-market difference worth noting for a reader comparing the two systems, not a reason to force a parallel worked example where the underlying mechanism doesn't actually match.
How to use it
Get both premium quotes — the actual continuation rate and a real quote for a comparable new individual policy — in writing before deciding, since continuation rates and moratorium-underwriting practices vary by insurer. Weigh the Exclusion Risk Value honestly against real treatment history, not hypothetical worst cases, and revisit the test if a new condition arises during the continuation period that would also have been excluded under fresh underwriting.
0 Comments